# Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency

Study · id `cardio:ct-nct07643818` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07643818](<https://clinicaltrials.gov/study/NCT07643818>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07643818

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 150 participants.

## Technical summary

Registry record NCT07643818. Randomized; double masking; primary purpose treatment. Start 2026-06-19 (actual); primary completion 2029-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT07643818, source copy `cardio:ctgov-nct07643818-2026-08-24`, retrieved 2026-10-26)
- Started: 2026-06-19 (actual) (ClinicalTrials.gov record NCT07643818, source copy `cardio:ctgov-nct07643818-2026-08-24`, retrieved 2026-10-26)
- Primary completion: 2029-07 (anticipated) (ClinicalTrials.gov record NCT07643818, source copy `cardio:ctgov-nct07643818-2026-08-24`, retrieved 2026-10-26)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07643818, source copy `cardio:ctgov-nct07643818-2026-08-24`, retrieved 2026-10-26)
- Countries: Jersey (ClinicalTrials.gov record NCT07643818, source copy `cardio:ctgov-nct07643818-2026-08-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07643818-2026-08-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency
- Acronym: ISLE HFpEF
- Condition: Heart Failure With Preserved Ejection Fraction (HFpEF
- Intervention (Drug): Ferric Derisomaltose
- Intervention (Drug): Placebo
- Lead sponsor: Government of Jersey
- Lead sponsor class: OTHER\_GOV
- Collaborator: University of Oxford
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as a collaborator: University of Oxford (`cardio:org-university-of-oxford`)

## Provenance

Content hash: 8ff15b53511609942e27d5bf9190dabb842c4248fc6785269c8a17656282a154
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
